Jacob J Adashek
Overview
Explore the profile of Jacob J Adashek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
1002
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Adashek J, Sapkota S, de Castro Luna R, Seiwert T
NPJ Precis Oncol
. 2023 Apr;
7(1):36.
PMID: 37041305
The advent of next-generation sequencing (NGS) has allowed for the identification of novel therapeutic targets for patients with uncommon cancers. It is well known that fusion translocations are potent driver...
22.
Gupta A, Kurzrock R, Adashek J
Cancers (Basel)
. 2023 Mar;
15(5).
PMID: 36900367
In the past two decades, molecular targeted therapy has revolutionized the treatment landscape of several malignancies. Lethal malignancies such as non-small cell lung cancer (NSCLC) have become a model for...
23.
Nelson B, Adashek J, Lin S, Subbiah V
Med
. 2023 Mar;
4(4):233-244.
PMID: 36893753
Interest in the abscopal effect has been rekindled over the past decade with the advent of immunotherapy. Although purportedly elusive, this phenomenon is being increasingly reported. Venturing further using a...
24.
Mason N, Joshi V, Adashek J, Kim Y, Shah S, Schneider A, et al.
Eur Urol Oncol
. 2023 Feb;
6(3):331-338.
PMID: 36797084
Background: The treatment landscape for metastatic renal cell carcinoma (mRCC) has significantly evolved in recent years. Without direct comparator trials, factors such as cost effectiveness (CE) are important to guide...
25.
Shaya J, Kato S, Adashek J, Patel H, Fanta P, Botta G, et al.
NPJ Genom Med
. 2023 Jan;
8(1):1.
PMID: 36670111
Despite progress, 2-year pancreatic cancer survival remains dismal. We evaluated a biomarker-driven, combination/N-of-one strategy in 18 patients (advanced/metastatic pancreatic cancer) (from Molecular Tumor Board). Targeted agents administered/patient = 2.5 (median)...
26.
Bevins N, Okamura R, Montesion M, Adashek J, Goodman A, Kurzrock R
J Immunother Precis Oncol
. 2022 Dec;
5(4):90-97.
PMID: 36483582
Introduction: Many studies have focused on the role of programmed death receptor ligand 1 (PD-L1) expression in predicting immunotherapy outcomes. Limited clinical data are available regarding the role of programmed...
27.
Nelson B, Adashek J, Lin S, Subbiah V
Cancer Med
. 2022 Nov;
12(6):6451-6465.
PMID: 36411943
Although the "abscopal phenomenon" has been described several decades ago, this phenomenon lately has been obtaining momentous traction with the dawn of immune-based therapies. There has been increased cross talk...
28.
Desai A, Adashek J, Reuss J, West H, Mansfield A
JAMA Oncol
. 2022 Nov;
9(1):135-142.
PMID: 36394834
Importance: Although cancer-related mortality continues to decline, lung cancer remains the No. 1 cause of cancer deaths in the US. Almost half of the patients with non-small cell lung cancer...
29.
Joshi R, Boichard A, Adashek J, Kurzrock R
Cancer Biol Ther
. 2022 Sep;
23(1):1-6.
PMID: 36171565
Next-generation sequencing data is fundamentally changing the clinical management of patients with cancer. The most frequent genomic alterations in malignancy are mutations and amplifications, with a subset of tumors having...
30.
Persha H, Kato S, De P, Adashek J, Sicklick J, Subbiah V, et al.
J Hematol Oncol
. 2022 Aug;
15(1):119.
PMID: 36031605
There is a paucity of information about molecularly driven therapy in osteosarcomas. We report a 31-year-old woman with chemotherapy-refractory metastatic osteosarcoma who was successfully treated with the combination of palbociclib...